View Investor Presentation

Cortendo AB 2016 Annual General Meeting / Årsstämma

Corporate Profile

Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Founded in 1996, the Company is publicly traded on the NASDAQ Global Market under the ticker symbol SBBP.

Read More

 |NASDAQ GS SBBP (Common Stock)
$3.00 + 0.40
Stock chart for: SBBP.O.  Currently trading at $3.00 with a 52 week high of $6.39 and a 52 week low of $2.00.
Data provided by Nasdaq. Minimum 15 minutes delayed.

Press Releases

Strongbridge Biopharma plc to Participate in the Canaccord Genuity Rare Disease and BioPharma One-on-One Day

February 2, 2017

DUBLIN, Ireland and TREVOSE, Pa., Feb. 02, 2017 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmace....

Read More

Strongbridge Biopharma plc Expands Commercial Capabilities with Two Rare Disease Executive Hires

January 9, 2017

Dave Bonnell and Scott Wilhoit to Focus on Sales, Marketing, and Market Access and Patient Services DUBLIN, Ireland and TREVOSE, Pa., Jan. 09, 2017 ....

Read More

View More

© 2016 Strongbridge Biopharma plc
STRONGBRIDGE BIOPHARMA is a trademark of Strongbridge Biopharma plc.
KEVEYIS ® is a registered trademark licensed exclusively in the US to Strongbridge Biopharma plc.
MLR010 V7 12/2016

900 Northbrook Drive, Suite 200
Trevose, PA 19053
United States
Phone: +1 610-254-9200